India Exchange Filings

NATCO Pharma FDA Inspection Update

Natco Pharma Ltd receives U.S. FDA EIR for its Parawada unit, with the inspection classified VAI after four Form 483 observations.

  • Inspection covered the finished dosage formulations unit in Parawada, Visakhapatnam.
  • The U.S. FDA conducted the inspection from 17–21 August 2026.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.